
|Articles|February 25, 2022
Current and Emerging Trends in Breast Cancer: HER2+ and HER2-Low
This publication provides a summary of key stakeholder insights on the role of antibody-drug conjugates in targeting HER2+ or HER2-low breast cancer and examines clinical trial data on treatment options for HER2+ breast cancer with brain metastases.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
First-Line Treatment Decisions in Metastatic Pancreatic Cancer: Setting the Stage
2
Mirvetuximab Soravtansine/Carboplatin Improves ORR But Fails to Extend PFS in FRα-High Recurrent Ovarian Cancer
3
Neoadjuvant Nivolumab Plus Ipilimumab Yields High PFS, OS Rates in Locally Advanced Cervical Cancer
4
Tolerability and ILD Prevention Drive Second-Line Treatment Sequencing in HER2+ NSCLC
5











































































